Research programme: Clostridium difficile monoclonal antibodies - Biolex
Alternative Names: C.difficile research programme - Biolex; Clostridium difficile antibodies research programme - BiolexLatest Information Update: 05 Feb 2018
At a glance
- Originator Biolex
- Class Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 05 Feb 2018 Discontinued - Preclinical for Clostridium difficile infections in USA (unspecified route)
- 19 Nov 2010 No development reported - Preclinical for Clostridium difficile infections in USA (unspecified route)
- 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex